CN Patent

CN113045541A — Egfr抑制剂新晶型及其制备方法

Assigned to Sunshine Lake Pharma Co Ltd · Expires 2021-06-29 · 5y expired

What this patent protects

本发明提供EGFR抑制剂新晶型及其制备方法，属于药物化学领域。所述晶型具有良好的稳定性和低毒性的特点。本发明所述制备方法通过将EGFR抑制剂与溶剂混悬搅拌，过滤，干燥，将干燥产品放置于潮湿空气中得到产品；所述制备方法操作简单，条件温和，结晶度好，易于工业化生产。

USPTO Abstract

本发明提供EGFR抑制剂新晶型及其制备方法，属于药物化学领域。所述晶型具有良好的稳定性和低毒性的特点。本发明所述制备方法通过将EGFR抑制剂与溶剂混悬搅拌，过滤，干燥，将干燥产品放置于潮湿空气中得到产品；所述制备方法操作简单，条件温和，结晶度好，易于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN113045541A
Jurisdiction
CN
Classification
—
Expires
2021-06-29
Drug substance claim
No
Drug product claim
No
Assignee
Sunshine Lake Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.